We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Automated Telephone Outreach With Speech Recognition to Improve Diabetes Care: A Randomized Controlled Study (ATO-SR-DM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00790530
Recruitment Status : Completed
First Posted : November 13, 2008
Last Update Posted : November 13, 2008
Sponsor:
Collaborator:
Information provided by:

Study Description
Brief Summary:
The purpose of this study is to evaluate the effectiveness of automated telephone outreach with speech recognition to improve diabetes care.

Condition or disease Intervention/treatment
Diabetes Mellitus Behavioral: Automated Telephone Outreach with Speech Recognition Other: Usual Care

Detailed Description:
Randomly allocate a total of 1200 health plan members with diabetes to automated telephone outreach with speech recognition (ATO-SR; N = 600) or usual care (N = 600). The intervention is a series of three calls, using automated calls, originating from the health plan, using interactive speech recognition technology, spaced approximately 4-6 weeks apart, to encourage participants to fulfill the recommended testing (dilated eye examinations, glycated hemoglobin, LDL-cholesterol, microalbumin) that had not been performed received in the preceding year.

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1200 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Health Services Research
Official Title: Automated Telephone Outreach With Speech Recognition to Improve Diabetes Care: A Randomized Controlled Study
Study Start Date : June 2006
Primary Completion Date : October 2007
Study Completion Date : October 2007
Arms and Interventions

Arm Intervention/treatment
Experimental: ATO-SR
Automated Telephone Outreach with Speech Recognition
Behavioral: Automated Telephone Outreach with Speech Recognition
Automated Telephone Outreach with Speech Recognition
No Intervention: Usual Care
Usual Care
Other: Usual Care
Usual Care


Outcome Measures

Primary Outcome Measures :
  1. Completion of dilated eye examination [ Time Frame: 12-months following intervention ]

Secondary Outcome Measures :
  1. Completion of glycated hemoglobin testing (HbA1c) [ Time Frame: one-year following intervention ]
  2. Completion of LDL-cholesterol testing [ Time Frame: one year following intervention ]
  3. Completion of microalbumin testing [ Time Frame: one-year following intervention ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Age 18 years or older
  • Diabetes, defined as either 1) filled a prescription for insulin or an oral hypoglycemic agent; or, 2) had two outpatient or one inpatient or two outpatients encounter claims with an ICD9-CM or CPT code indicating diabetes.
  • Gap in a key diabetes management metric as evidenced by no claim for a dilated eye examination in the prior 15 months and no claim for one or more of the following tests: glycated hemoglobin, LDL-cholesterol, or microalbumin. (Individuals with evidence of having received ACE-inhibitors or angiotensin receptor blockers were considered to have had a microalbumin test.)

Exclusion Criteria:

  • No primary care clinician in the data base
  • Those who had previously asked the health plan to exclude them from research or quality improvement
  • Women whose claim records contained diagnoses suggesting gestational diabetes
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00790530


Locations
United States, Massachusetts
Harvard Pilgrim Health Care
Boston, Massachusetts, United States, 02215
Sponsors and Collaborators
Harvard Pilgrim Health Care
American Diabetes Association
Investigators
Principal Investigator: Steven R Simon, MD Harvard Pilgrim Health Care
More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Steven R. Simon, Principal Investigator, Harvard Pilgrim Health Care
ClinicalTrials.gov Identifier: NCT00790530     History of Changes
Other Study ID Numbers: 1-05-JF-40
First Posted: November 13, 2008    Key Record Dates
Last Update Posted: November 13, 2008
Last Verified: November 2008

Keywords provided by Harvard Pilgrim Health Care:
Diabetes
Information Technology
Health Plans

Additional relevant MeSH terms:
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases